Dosing & Administration

Indication
  • Ranexa is indicated for the treatment of chronic angina.
  • Ranexa may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers.
Titrate to 1000 mg BID* based on clinical symptoms1
  • The maximum recommended daily dose of Ranexa® is 1000 mg BID*
  • Limit the dose of Ranexa to 500 mg BID in patients on moderate CYP3A inhibitors (e.g., diltiazem, verapamil, erythromycin, fluconazole, and grapefruit juice or grapefruit-containing products)
  • When used with P-gp inhibitors (e.g., cyclosporine), the exposure to Ranexa may be increased. Titrate Ranexa based on clinical response
  • Ranexa should be swallowed whole; do not crush, break, or chew

Across clinical trials, 87% of patients taking Ranexa were on 1000 mg BID.2

Limit the dose of Ranexa to 500 mg BID when coadministered with diltiazem, verapamil, or other moderate CYP3A inhibitors.

BID=twice a day.

Treatment Considerations icon of checklist

Treatment considerations

Review the clinical properties of Ranexa, including information about:

  • Rate-pressure product
  • Tolerance to therapy
  • Dose-free interval
  • PDE-5 inhibitors
Learn more
References:

1. Ranexa [package insert]. Foster City, CA: Gilead Sciences, Inc.; January 2016.

2. Data on file. Gilead Sciences, Inc.

Important Safety Information
Contraindications